GleamWall
中文EN

HOWL Werewolf Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1785530 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY61.4%
TTM EPS YoY63.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-154.6%
ROA-46.0%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets84.2%
Debt / equity0.00x
Current ratio1.19x
Interest coverage-7.97x

Cash quality & payout

Operating cash flow / net income0.85x
Accruals ratio-6.8%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$2.17M$6.16M$8.18M$6.93M$11.63M$13.14M$13.12M$15.73M
SG&A expense$7.88M$7.68M$5.09M$2.48M$4.09M$4.40M$4.87M$4.62M
Operating income-$10.05M$7.16M-$13.27M-$9.42M-$15.73M-$17.54M-$17.99M-$20.35M
Interest expense$0$475,000$1.37M$1.37M$1.34M$1.30M$1.26M$1.27M
Net income-$9.88M$3.67M-$13.53M-$8.38M-$16.37M-$17.98M-$18.09M-$20.40M
EBITDA-$8.79M$9.61M-$12.87M-$9.02M-$15.32M-$17.14M-$17.57M-$19.91M
EPS (basic)-0.200.08-0.28—-0.36-0.40-0.40—
EPS (diluted)-0.200.08-0.28—-0.36-0.40-0.40—
Weighted avg. shares (diluted)48.60M48.60M49.39M—45.80M44.98M44.83M—
Balance sheet
Cash & equivalents$41.87M$21.99M$46.45M$57.05M$65.71M$77.60M$92.04M$112.22M
Current assets$42.75M$22.89M$48.73M$58.59M$68.17M$80.44M$94.46M$113.07M
PP&E, net$0$1.26M$4.29M$4.69M$5.09M$5.49M$5.90M$6.32M
Total assets$42.75M$24.16M$58.02M$69.40M$79.63M$92.57M$107.24M$126.93M
Current liabilities$35.99M$7.86M$38.52M$36.15M$17.60M$15.17M$11.67M$15.18M
Long-term debt——$32.09M$32.09M$32.09M$32.09M$32.09M$32.09M
Total debt——$32.09M$32.09M$32.09M$32.09M$32.09M$32.09M
Total liabilities$35.99M$7.86M$45.82M$44.59M$50.01M$51.10M$49.93M$53.54M
Shareholders' equity$6.76M$16.29M$12.20M$24.80M$29.61M$41.46M$57.31M$73.39M
Net debt——-$14.37M-$24.96M-$33.63M-$45.51M-$59.96M-$80.13M
Shares outstanding48.60M48.60M48.60M48.60M47.27M45.34M44.83M44.83M
Cash flow statement
Operating cash flow-$8.97M$6.63M-$10.60M-$11.02M-$15.16M-$15.16M-$18.95M-$14.25M
Capital expenditure———$0$0$0$0$123,000
Free cash flow———-$11.02M-$15.16M-$15.16M-$18.95M-$14.38M
Investing cash flow$28.85M——$0$0$0$0-$123,000
Financing cash flow$0——$2.37M$3.27M$388,000$0$2.55M
Depreciation & amortization$1.26M$2.45M$398,000$400,000$402,000$406,000$426,000$442,000
Stock-based compensation$344,000$419,000$929,000$1.21M$1.23M$1.79M$2.01M$1.91M

Free plan shows the latest 8 periods; Pro shows all 27 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.